Clinical Trial Update: Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intravitreal aflibercept vs ranibizumab for rubeosis iridis in glaucoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma
• Rubeosis Iridis

Drugs mentioned

• Eylea (aflibercept) (aflibercept)
• Lucentis (ranibizumab) (ranibizumab)

Snippet

Sponsor: Instituto de Olhos de Goiania | Conditions: Glaucoma, Rubeosis Iridis | Phase 3 | Status: COMPLETED